Why the study?
Does rivaroxaban reduce symptomatic thromboembolic events compared to standard-of-care in patients undergoing major orthopaedic surgery?
Does rivaroxaban reduce symptomatic thromboembolic events compared to standard-of-care in patients undergoing major orthopaedic surgery?
In a large real-world cohort, rivaroxaban reduced symptomatic thromboembolic events compared to standard pharmacological prophylaxis after major orthopaedic surgery, with a similar safety profile.
No takes yet. Share an insight, caveat, or question.
May support rivaroxaban for VTE prophylaxis after orthopaedic surgery; extends RCT data but hypothesis-generating pending randomized confirmation.
Haas et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: